Although the field is still in its infancy, combining cytotoxic therapy with pharmaceutical interventions that alter the circadian phase or the function of clock proteins has the possibility of enhancing therapeutic indices, increasing tolerability, and improving breast cancer outcomes. Here, CLOCK is linked to breast cancer.